Calimmune (Tucson, AZ) Approved to Treat Second Group in HIV Stem Cell Gene Modification Study

June 25, 2014

San Diego, CA – Calimmune today announced encouraging safety data from its innovative gene-based stem cell therapy, Cal-1-being developed to help cure individuals infected with HIV. The company can now begin treating the second group of patients in the trial, which is being funded in part by a grant from the California Institute for Regenerative Medicine (CIRM).Continue reading

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome